Suggested Remit: To appraise the clinical and cost effectiveness of nintedanib with pemetrexed and cisplatin followed by nintedanib monotherapy within its marketing authorisation for untreated unresectable malignant pleural mesothelioma.
The company have informed us that they are no longer seeking regulatory approval in this indication. Therefore the appraisal is suspended.
- Status:
- Discontinued
- Technology type:
- Medicine
- Decision:
- Prioritised
- Process:
- TA
- ID number:
- 1424
Email enquiries
If you have any queries please email scheduling@nice.org.uk
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 25 August 2022 | Discontinued. The company have informed us that they are no longer seeking regulatory approval in this indication. Therefore the appraisal is suspended. |
| 20 July 2020 | Note added to the project documents |
| 09 March 2020 | Note added to the project documents |
| 09 March 2020 | Suspended. Topic is suspended |
| 11 June 2018 - 09 July 2018 | Consultation on suggested remit, draft scope and provisional matrix of consultees and commentators |
| 24 April 2018 | In progress. DHSC Referral Received |
For further information on our processes and methods, please see our CHTE processes and methods manual